Integris Wealth Management LLC Has $918,000 Position in AbbVie Inc. (NYSE:ABBV)

Integris Wealth Management LLC lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 5.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,164 shares of the company’s stock after purchasing an additional 259 shares during the quarter. Integris Wealth Management LLC’s holdings in AbbVie were worth $918,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of ABBV. Creekside Partners acquired a new stake in AbbVie in the 2nd quarter valued at approximately $336,000. Anchor Investment Management LLC raised its holdings in shares of AbbVie by 0.8% in the second quarter. Anchor Investment Management LLC now owns 86,189 shares of the company’s stock valued at $14,783,000 after purchasing an additional 691 shares during the last quarter. Mattson Financial Services LLC bought a new stake in shares of AbbVie in the second quarter worth $1,158,000. Neville Rodie & Shaw Inc. boosted its holdings in AbbVie by 5.4% during the third quarter. Neville Rodie & Shaw Inc. now owns 100,915 shares of the company’s stock worth $19,929,000 after purchasing an additional 5,172 shares during the last quarter. Finally, M&R Capital Management Inc. grew its position in AbbVie by 7.5% in the third quarter. M&R Capital Management Inc. now owns 16,447 shares of the company’s stock valued at $3,248,000 after purchasing an additional 1,149 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of recent research reports. Daiwa Capital Markets downgraded shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 price objective for the company. in a research note on Thursday, December 5th. Wells Fargo & Company raised their price target on AbbVie to $195.00 and gave the company a “buy” rating in a research note on Tuesday, November 19th. Guggenheim upped their price objective on AbbVie from $212.00 to $221.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Piper Sandler Companies reissued an “overweight” rating and issued a $220.00 target price on shares of AbbVie in a research note on Tuesday, December 17th. Finally, Truist Financial dropped their price target on shares of AbbVie from $215.00 to $211.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.00.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $175.54 on Friday. AbbVie Inc. has a 12-month low of $153.58 and a 12-month high of $207.32. The company’s 50 day moving average price is $176.37 and its two-hundred day moving average price is $184.90. The firm has a market cap of $310.21 billion, a PE ratio of 60.95, a PEG ratio of 1.77 and a beta of 0.58. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.92 by $0.08. The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.28 billion. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.95 earnings per share. Equities research analysts predict that AbbVie Inc. will post 10.09 earnings per share for the current year.

Insider Activity

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.